Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
Open Access
- 15 December 2010
- journal article
- research article
- Published by Springer Nature in Pituitary
- Vol. 14 (2) , 184-193
Abstract
Acromegaly is a rare disease with a multifaceted clinical presentation. In 90–95% of patients with acromegaly, the disease is caused by a growth hormone (GH)-secreting pituitary adenoma with elevated GH levels that ultimately induce excessive hepatic secretion of insulin-like growth factor-1 (IGF-1). Somatostatin receptor ligands (SRLs) are considered the standard medical choice for the treatment of acromegaly, and normalization of GH and IGF-1 is attainable with effective therapy. This review aims to summarize the literature relative to SRL dose escalation therapy in patients with acromegaly. A United States National Library of Medicine PubMed search of SRL’s was conducted using the following search terms: ((((LAR) OR ATG) OR octreotide) OR lanreotide Autogel) AND acromegaly. Related articles in non peer-reviewed journals were excluded. The rationale and benefits of SRL dose optimization therapy were investigated with emphasis on describing the clinical recognition, treatment, and management of patients with acromegaly. We found that dose escalation could provide additional biochemical control of acromegaly in patients who are inadequately controlled with conventional starting doses of octreotide LAR and lanreotide Autogel®. Furthermore, patients should routinely have their GH and IGF-1 levels closely monitored and their SRL dose increased or decreased thereafter according to individual response.Keywords
This publication has 64 references indexed in Scilit:
- Primary treatment of acromegaly with high-dose lanreotide: a case seriesJournal of Medical Case Reports, 2010
- Medical Therapy of AcromegalyDrugs, 2009
- From somatostatin to octreotide LAR: evolution of a somatostatin analogueCurrent Medical Research and Opinion, 2009
- Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extensionPituitary, 2009
- Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open‐label, multicentre studyClinical Endocrinology, 2009
- Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic reviewPituitary, 2009
- Control of IGF‐I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegalyClinical Endocrinology, 2008
- Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegalyEuropean Journal of Endocrinology, 2007
- A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegalyClinical Endocrinology, 2007
- Glucose homeostasis in acromegaly: effects of long‐acting somatostatin analogues treatmentClinical Endocrinology, 2003